Active — Not RecruitingPhase 3

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

United States120 participantsStarted 2011-01-05

Plain-language summary

This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is to learn if dynamic contrast enhanced computed tomography (DCE-CT) scans can help researchers learn if the study drug received as part of study 2010-0085 (either everolimus, bevacizumab, or pazopanib) is working.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient must be enrolled or being considered for enrollment on protocol 2010-0085.
✓. Patients must have metastatic renal cell carcinoma (RCC).
✓. Age \>/= 18 years.
✓. Subjects must have adequate renal function as defined by serum creatinine \< 1.5x upper limit of normal.

Exclusion criteria

✕. Radiotherapy: Subjects may not have received prior radiotherapy to the index lesion within 4 weeks
✕. Female subjects who are pregnant or lactating.
✕. Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment).
✕. Allergy to CT contrast media requiring the administration of steroid prophylaxis.

What they're measuring

Tumor Blood Flow (BF) Reduction

Timeframe: From 4 weeks prior to first dose to 8 weeks post treatment

Trial details

NCT IDNCT01224288

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-04-30

View on ClinicalTrials.gov More Renal Cell Carcinoma trials